ROXOLYTE F.C TABLET Tablet

About ROXOLYTE F.C TABLET 10 mg

ROXOLYTE F.C TABLET is a 10 mg film-coated tablet containing rivaroxaban, an oral anticoagulant. It is used to help prevent blood clots in certain conditions as decided by a doctor.

There are 19 brands of Rivaroxaban listed in Bangladesh. The lowest listed price is Rivadel 2.5 Tablet at ৳ 5 per unit.

What is ROXOLYTE F.C TABLET 10 mg?

ROXOLYTE F.C TABLET is a film-coated tablet that contains rivaroxaban 10 mg. Rivaroxaban belongs to a group of medicines called oral anticoagulants, which help reduce the risk of harmful blood clots. It works by blocking a specific clotting factor in the blood. This medicine is available only on prescription, and the doctor decides the right dose and duration for each person. It is important to take it exactly as instructed and not to stop it without medical advice, because stopping suddenly can raise the risk of clots. The pack size and price are not provided here; ask your pharmacist for details.

Uses of ROXOLYTE F.C TABLET

ROXOLYTE F.C TABLET is used in adults to help prevent serious blood clots in conditions such as atrial fibrillation, after certain heart events, or in the treatment of deep vein thrombosis and pulmonary embolism. The doctor will confirm whether it is suitable for you. It is not a painkiller or a general tonic and should not be used for other purposes. Always follow your doctor's advice about why and for how long you need it.

How to use ROXOLYTE F.C TABLET

Take ROXOLYTE F.C TABLET by mouth, with or without food, unless your doctor gives different instructions. Swallow the tablet whole with water; do not crush or chew it. The doctor decides the dose, how often to take it, and for how long. Do not change the dose or stop the medicine on your own, even if you feel well, because stopping suddenly can increase the risk of clots. If you miss a dose, ask your doctor or pharmacist what to do.

Side effects of ROXOLYTE F.C TABLET

The most common side effect of rivaroxaban is an increased chance of bleeding. This can include nosebleeds, gum bleeding, easy bruising, or longer bleeding from small cuts. More serious bleeding can occur, including bleeding in the spine or brain, and there is an increased risk of stroke if the medicine is stopped suddenly in people with nonvalvular atrial fibrillation. Seek medical help right away if you have unusual or severe bleeding, black stools, coughing up blood, or a severe headache.

Safety and precautions

Before taking ROXOLYTE F.C TABLET, tell your doctor if you have a bleeding disorder, uncontrolled high blood pressure, stomach or bowel disease, eye blood vessel problems, or a history of lung bleeding. Also mention all other medicines you take, including painkillers, blood thinners, or herbal products, as some can raise the risk of bleeding or change how this medicine works. It is not recommended during pregnancy or breastfeeding without specialist advice, as safety has not been established. Do not start or stop it without your doctor's guidance.

Frequently asked questions

What kind of medicine is ROXOLYTE F.C TABLET and what is it used for?

It is an oral anticoagulant containing rivaroxaban. It is used in adults to help prevent harmful blood clots in conditions such as atrial fibrillation, after certain heart events, and in the treatment of deep vein thrombosis and pulmonary embolism. Your doctor will decide if it is right for you.

How should I take ROXOLYTE F.C TABLET?

Take it by mouth with water, with or without food, as your doctor advises. Swallow it whole. The doctor decides the dose and how long you need it. Do not change or stop the medicine on your own, because stopping suddenly can increase the risk of clots.

What does the dosage form and strength mean?

ROXOLYTE F.C TABLET is a film-coated tablet, meaning it has a thin coating to make it easier to swallow and protect it. The strength is 10 mg, which is the amount of rivaroxaban in each tablet. Your doctor will decide how many tablets you need.

Can I stop taking ROXOLYTE F.C TABLET on my own?

No. Stopping this medicine early without another anticoagulant can raise the risk of blood clots. Always talk to your doctor before stopping or changing it, even if you feel well. Your doctor will tell you how and when to stop safely if needed.

Indications

Rivaroxaban 2.5 mg:
  • For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg ... Read moreRivaroxaban 2.5 mg:
  • For the prevention of atherothrombotic events in adult patients after an Acute Coronary Syndrome (ACS) with elevated cardiac biomarkers (Troponin or CK-MB). It is co-administered with Aspirin alone or with Aspirin plus Clopidogrel orTidopidine.
Rivaroxaban 10-20 mg:
  • To reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  • Deep vein thrombosis (DVT) & pulmonary embolism (PE) and reduction in the risk of recurrence of DVT and of PE
  • For the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery

Pharmacology

Rivaroxaban is a highly selective direct factor Xa inhibitor. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibits thrombin formation. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated.

Dosage & Administration

Rivaroxaban 2.5 mg:
  • The recommended dose: 2.5 mg twice daily. Patients should also take a daily dose of 75-100 mg Aspirin or a daily dose of 75-100 mg Aspirin in addition to either a daily dose of 75 mg clopidogrel or a standard daily dose of ticlopidine.
Rivaroxaban 10-20 mg:
  • Nonvalvular Atrial Fibrillation: For patients with Creatinin Clearance >50 mL/min: 20 mg orally, once daily with the evening meal. For patients with Creatinin Clearance 15-50 ml/min: 15 mg orally, once daily with the evening meal.
  • Treatment of DVT & PE: 15 mg orally twice daily with food for the first 21 days for the initial treatment of acute DVT or PE. After the initial treatment period, 20 mg orally once daily with food for the remaining treatment.
  • Prevention in the risk of recurrence of DVT and of PE: 20 mg once daily with food.
  • Prophylaxis of DVT following Hip replacement surgery: 10 mg once daily for 35 days.
  • Prophylaxis of DVT following knee replacement surgery: 10 mg once daily for 12 days.
May be taken with or without food.

Interaction

Concomitant use with drugs that are combined P-gp and CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, erythromycin, fluconazole, diltiazem, verapamil, dronedarone) increases in Rivaroxaban exposure and pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation), that’s why should be avoided. Co-administration of Rivaroxaban with a combined P-gp and strong CYP3A4 inducer (e.g., rifampicin, phenytoin, carbamazepine) decreases the efficacy of Rivaroxaban and also should be avoided. The concomitant use of other drugs like anti-platelet agents, heparin, fibrinolytic therapy, NSAIDs may cause an increased risk of bleeding.

Contraindications

It is contraindicated in patients with known hypersensitivity of Rivaroxaban or any of the excipients of the product. It is also contraindicated in patients with active pathological bleeding.

Side Effects

The most common side effects of Rivaroxaban have increased chance of bleeding, spinal or epidural hematoma and increased risk of stroke after discontinuation in nonvalvular atrial fibrillation.

Pregnancy & Lactation

Rivaroxaban is a pregnancy category C drug. There are no adequate or well-controlled studies of Rivaroxaban in pregnant women, and dosing for pregnant women has not been established. It is not known if Rivaroxaban is excreted in human milk. The safety and efficacy of Rivaroxaban has not been established in breastfeeding women.

Precautions & Warnings

Early discontinuation of Rivaroxaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. Rivaroxaban increases the risk of bleeding that can be fatal in presence of following risk factors- bleeding disorders, uncontrolled severe arterial hypertension, gastrointestinal disease (e.g., inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease), vascular retinopathy, bronchiectasis, history of pulmonary bleeding. Signs or symptoms of neurological impairment should be monitored in case of neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture as epidural or spinal hematoma can occur. Rivaroxaban is not recommended in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

Overdose Effects

Overdose of Rivaroxaban may lead to hemorrhage. Rivaroxaban systemic exposure is not further increased at single doses >50 mg due to limited absorption. A specific antidote for Rivaroxaban is not available. The use of activated charcoal to reduce absorption in case of Rivaroxaban overdose may be considered. Partial reversal of laboratory anticoagulation parameters may be achieved with use of plasma products.

Storage Conditions

Store in a cool (below 30°C) & dry place protected from light. Keep away from the reach of children.

Alternative brands of Rivaroxaban

Other brands with the same generic name, cheapest first.

See all 19 brands

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.